Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer

Journal of Chemotherapy

Volumn 18, Issue 1, 2006, Pages 90-97

  Montemurro, Filippo ^a   Gatti, M ^a   Redana, S ^a   Jacomuzzi, M E ^a   Nanni, D ^a   Durando, A ^b   Popolo, M ^b   Ponzone, R ^a   Rossi, A ^c   Albieri, V ^a   Valabrega, G ^a   Sismondi, P ^a   Gabriele, P ^a   Aglietta, M ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b S ANNA HOSPITAL   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

Author keywords

Breast cancer; Concurrent radiotherapy and chemotherapy; Cyclophosphamide; Methotrexate and 5 fluorouracil (CMF); Toxicity

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; METHOTREXATE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; DIARRHEA; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; VOMITING;

EID: 33645097580     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.1.90     Document Type: Article

References (28)

1. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539-69.
2. Whelan T, Olivotto I, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: breast radiotherapy after breast-conserving surgery (summary of the 2003 update). Can Med Assoc J 2003; 168: 437-9.
3. Truong PT, Olivotto IA, Whelan TJ, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. Can Med Assoc J 2004; 170: 1263-73.
4. Hanna YM, Baglan KL, Stromberg JS, Vicini FA, Decker A. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 2002; 8: 149-53.
5. Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001; 93: 1806-11.
6. Isaac N, Panzarella T, Lau A, et al. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer 2002; 95: 696-703.
7. Faul C, Brufsky A, Gerszten K, et al. Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery. Eur J Cancer 2003; 39: 763-8.
8. Buchholz TA, Ustin-Seymour MM, Moe RE, et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1993; 26: 23-35.
9. Leonard CE, Wood ME, Zhen B, et al. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol 1995; 13: 2906-15.
10. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334: 1356-61.
11. Buchholz TA, Hunt KK, Amosson CM, et al. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am 1999; 5: 159-64.
12. Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005; 23: 1934-40.
13. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-5.
14. Locatelli M, Colleoni M, Noberasco C, et al. Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen). Ann Oncol 1999; 10: 1394-5.
15. International Commission on Radiation Units and Measurements. ICRU report 50, Prescribing, Recording and Reporting Photon Beam Therapy, 1 September 1993.
16. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21: 4524-31.
17. Denham JW, Hamilton CS, Christie D, et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer-toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Institution study. Int J Radiat Oncol Biol Phys 1995; 31: 305-13.
18. Fiets WE, van Helvoirt RP, Nortier JW, van dT, I, Struikmans H. Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients, a prospective, comparative, non-randomised study. Eur J Cancer 2003; 39: 1081-8.
19. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352: 930-42.
20. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-83.
21. Mamounas EP, Bryant J, Lembersky C, et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 2003; 22: 4-12.
22. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-13.
23. Roila F, Ballatori E, Patoia L, et al. Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Ann Oncol 2003; 14: 843-8.
24. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. Br Med J 2005; 330: 217-20.
25. Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. J Clin Oncol 2004; 22: 1614-20.
26. Earl H, Iddawela M. Epirubicin as adjuvant therapy in breast cancer. Expert Rev Anticancer Ther 2004; 4: 89-95.
27. De Placido S, De Laurentiis M, De Lena M, et al. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br J Cancer 2005; 92: 467-74.
28. Eiermann W, Sabadell D, Baselga J, et al. European cooperative trial in operable breast cancer (ECTO): No increased risk of local breast tumor recurrence (LBR) as first and only event after primary systemic therapy (PST). Proc Am Soc Clin Oncol 2003; 22: 10-abst.37.